Latest Wound Care News

Page 1 of 6
AVITA Medical has raised its 2026 revenue guidance for a second time after third-quarter revenue climbed 53% year on year. The company also drew a further US$10 million under its credit facility and removed its going-concern qualification, although it remains loss-making and highly leveraged.
Victor Sage
Victor Sage
6 Nov 2026
Solventum has raised its full-year adjusted earnings forecast after a third quarter shaped by the expected reversal of ERP-related advance orders. The healthcare technology company also completed its major system cutovers and reported strong growth in Advanced Wound Care.
Ada Torres
Ada Torres
6 Nov 2026
Holista Colltech reported positive adjusted operating cash flow of A$318,000 for the September quarter, although statutory cash flow remained negative after its final ProImmune settlement payment. The company also pushed the planned start of its Collie collagen plant from December 2026 to May-July 2027, while ending the quarter with just A$23,000 in cash.
Victor Sage
Victor Sage
30 Oct 2026
Tissue Repair has increased its US Phase III chronic wound trial to approximately 112 randomised patients while shifting focus towards an April 2027 FDA 510(k) submission. The company also reported $4.74 million in cash, Australian availability of all three TR Pro+ formats and a planned $1 million share buy-back.
Ada Torres
Ada Torres
29 Oct 2026
ReNerve’s October AGM presentation points to sharply higher sales, a growing US distribution network and a broader nerve repair pipeline. The company is also progressing a 240-patient NervAlign clinical study while relying on a $5 million RiverFort funding facility to support expansion.
Victor Sage
Victor Sage
5 Oct 2026
PolyNovo delivered 16.1% revenue growth and a sharp improvement in operating cash flow in FY26, despite a lower statutory profit after a prior-year tax benefit and a fire-related write-off. The ASX-listed wound-care company now expects to lodge its U.S. PMA application for NovoSorb BTM before the end of 2026.
Victor Sage
Victor Sage
15 Sept 2026
PolyNovo reported a 16.1% rise in FY26 revenue to AUD 150 million, driven by strong global sales and manufacturing expansion, yet net profit fell 44% due to a significant asset write-off from an R&D centre fire and lower tax benefits.
Ada Torres
Ada Torres
26 Aug 2026
AVITA Medical's PermeaDerm biosynthetic wound matrix delivers clinical outcomes on par with allograft while slashing treatment costs by 70%, according to a new multicenter study.
Ada Torres
Ada Torres
19 Aug 2026
PolyNovo has delivered solid FY26 revenue growth of 16.1%, driven by commercial sales expansion and improved manufacturing output, while progressing insurance recovery from its R&D centre fire.
Ada Torres
Ada Torres
23 July 2026
AVITA Medical reported a 4% revenue increase in Q1 2026 with a narrowed net loss, underpinned by a new BARDA contract and promising Cohealyx clinical data. Leadership changes and regulatory approvals support a confident outlook.
Ada Torres
Ada Torres
15 May 2026
AVITA Medical’s Cohealyx-I study interim results show a significant acceleration in skin grafting time for full-thickness wounds, reducing mean time to graft from 33.2 to 13.6 days. The ongoing trial’s promising data could reshape wound care protocols.
Ada Torres
Ada Torres
15 Apr 2026
AVITA Medical has lodged a new $200 million shelf registration with the SEC, renewing its capacity to issue various securities in the US market. While no immediate capital raising is planned, this move preserves the company’s financial agility for future growth opportunities.
Ada Torres
Ada Torres
1 Apr 2026

Browse the archive

Full archive